532 related articles for article (PubMed ID: 9600309)
1. Improved humoral and cellular immune responses against the gp120 V3 loop of HIV-1 following genetic immunization with a chimeric DNA vaccine encoding the V3 inserted into the hepatitis B surface antigen.
Fomsgaard A; Nielsen HV; Bryder K; Nielsen C; Machuca R; Bruun L; Hansen J; Buus S
Scand J Immunol; 1998 Apr; 47(4):289-95. PubMed ID: 9600309
[TBL] [Abstract][Full Text] [Related]
2. Brucella abortus conjugated with a peptide derived from the V3 loop of human immunodeficiency virus (HIV) type 1 induces HIV-specific cytotoxic T-cell responses in normal and in CD4+ cell-depleted BALB/c mice.
Lapham C; Golding B; Inman J; Blackburn R; Manischewitz J; Highet P; Golding H
J Virol; 1996 May; 70(5):3084-92. PubMed ID: 8627787
[TBL] [Abstract][Full Text] [Related]
3. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
Peet NM; McKeating JA; de Souza JB; Roitt IM; Delves PJ; Lund T
Virology; 1998 Nov; 251(1):59-70. PubMed ID: 9813203
[TBL] [Abstract][Full Text] [Related]
4. Improved immunogenicity of HIV-1 epitopes in HBsAg chimeric DNA vaccine plasmids by structural mutations of HBsAg.
Bryder K; Sbai H; Nielsen HV; Corbet S; Nielsen C; Whalen RG; Fomsgaard A
DNA Cell Biol; 1999 Mar; 18(3):219-25. PubMed ID: 10098603
[TBL] [Abstract][Full Text] [Related]
5. Efficient CD8+ T cell response to the HIV-env V3 loop epitope from multiple virus isolates by a DNA prime/vaccinia virus boost (rWR and rMVA strains) immunization regime and enhancement by the cytokine IFN-gamma.
Gómez CE; Abaitua F; Rodríguez D; Esteban M
Virus Res; 2004 Sep; 105(1):11-22. PubMed ID: 15325077
[TBL] [Abstract][Full Text] [Related]
6. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
Kang CY; Luo L; Wainberg MA; Li Y
Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
[TBL] [Abstract][Full Text] [Related]
7. Characterization of an internal permissive site in the cholera toxin B-subunit and insertion of epitopes from human immunodeficiency virus-1, hepatitis B virus and enterotoxigenic Escherichia coli.
Bckström M; Holmgren J; Schödel F; Lebens M
Gene; 1995 Nov; 165(2):163-71. PubMed ID: 8522171
[TBL] [Abstract][Full Text] [Related]
8. Priming of class I-restricted cytotoxic T lymphocytes by vaccination with recombinant protein antigens.
Schirmbeck R; Deml L; Melber K; Wolf H; Wagner R; Reimann J
Vaccine; 1995 Jun; 13(9):857-65. PubMed ID: 7483809
[TBL] [Abstract][Full Text] [Related]
9. A universal T cell epitope-containing peptide from hepatitis B surface antigen can enhance antibody specific for HIV gp120.
Greenstein JL; Schad VC; Goodwin WH; Brauer AB; Bollinger BK; Chin RD; Kuo MC
J Immunol; 1992 Jun; 148(12):3970-7. PubMed ID: 1376346
[TBL] [Abstract][Full Text] [Related]
10. Improvement of hepatitis B virus DNA vaccines by plasmids coexpressing hepatitis B surface antigen and interleukin-2.
Chow YH; Huang WL; Chi WK; Chu YD; Tao MH
J Virol; 1997 Jan; 71(1):169-78. PubMed ID: 8985336
[TBL] [Abstract][Full Text] [Related]
11. Priming biologically active antibody responses against an isolated, conformational viral epitope by DNA vaccination.
Riedl P; El-Kholy S; Reimann J; Schirmbeck R
J Immunol; 2002 Aug; 169(3):1251-60. PubMed ID: 12133946
[TBL] [Abstract][Full Text] [Related]
12. Enhanced CD8+ T cell immune response against a V3 loop multi-epitope polypeptide (TAB13) of HIV-1 Env after priming with purified fusion protein and booster with modified vaccinia virus Ankara (MVA-TAB) recombinant: a comparison of humoral and cellular immune responses with the vaccinia virus Western Reserve (WR) vector.
Gómez CE; Rodríguez D; Rodríguez JR; Abaitua F; Duarte C; Esteban M
Vaccine; 2001 Dec; 20(5-6):961-71. PubMed ID: 11738764
[TBL] [Abstract][Full Text] [Related]
13. Construction, biological activity, and immunogenicity of synthetic envelope DNA vaccines based on a primary, CCR5-tropic, early HIV type 1 isolate (BX08) with human codons.
Corbet S; Vinner L; Hougaard DM; Bryder K; Nielsen HV; Nielsen C; Fomsgaard A
AIDS Res Hum Retroviruses; 2000 Dec; 16(18):1997-2008. PubMed ID: 11153083
[TBL] [Abstract][Full Text] [Related]
14. Targeting murine immune responses to selected T cell- or antibody-defined determinants of the hepatitis B surface antigen by plasmid DNA vaccines encoding chimeric antigen.
Schirmbeck R; Zheng X; Roggendorf M; Geissler M; Chisari FV; Reimann J; Lu M
J Immunol; 2001 Jan; 166(2):1405-13. PubMed ID: 11145726
[TBL] [Abstract][Full Text] [Related]
15. Immunization with a plasmid encoding a modified hepatitis B surface antigen carrying the receptor binding site for hepatocytes.
Hui J; Mancini M; Li G; Wang Y; Tiollais P; Michel ML
Vaccine; 1999 Mar; 17(13-14):1711-8. PubMed ID: 10194827
[TBL] [Abstract][Full Text] [Related]
16. Comparisons of DNA-mediated immunization procedures directed against surface glycoproteins of human immunodeficiency virus type-1 and hepatitis B virus.
Fomsgaard A; Nielsen HV; Nielsen C; Johansson K; Machuca R; Bruun L; Hansen J; Buus S
APMIS; 1998 Jun; 106(6):636-46. PubMed ID: 9725796
[TBL] [Abstract][Full Text] [Related]
17. Characterization of complex B cell epitopes on woodchuck hepatitis virus surface antigens by using plasmids encoding chimeric proteins and DNA immunization.
Zheng X; Schirmbeck R; Hilken G; Waters JA; Yang D; Reimann J; Roggendorf M; Lu M
Virology; 2002 Mar; 294(2):342-53. PubMed ID: 12009876
[TBL] [Abstract][Full Text] [Related]
18. HIV-1 DNA vaccine efficacy is enhanced by coadministration with plasmid encoding IFN-alpha.
Jiang W; Ren L; Jin N
J Virol Methods; 2007 Dec; 146(1-2):266-73. PubMed ID: 17868910
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis B surface antigen vector delivers protective cytotoxic T-lymphocyte responses to disease-relevant foreign epitopes.
Woo WP; Doan T; Herd KA; Netter HJ; Tindle RW
J Virol; 2006 Apr; 80(8):3975-84. PubMed ID: 16571814
[TBL] [Abstract][Full Text] [Related]
20. Single peptide and anti-idiotype based immunizations can broaden the antibody response against the variable V3 domain of HIV-1 in mice.
Boudet F; Keller H; Kieny MP; Thèze J
Mol Immunol; 1995 May; 32(7):449-57. PubMed ID: 7783749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
